Botulinum toxin to treat severe vocal cord dysfunction in asthma patients

A world-first clinical trial is using botulinum toxin (otherwise known as Botox) to treat severe vocal cord dysfunction in patients with asthma.

Vocal Cord Dysfunction is a condition where the vocal cords move in an abnormal, uncoordinated way, causing episodes of severe breathlessness and wheezing. This can be mistaken for a severe asthma attack which fails to respond to conventional asthma treatment.

The research was led by Monash University Department of Medicine's Professor Philip Bardin, who is also Director of Respiratory and Sleep Medicine for Monash Health, and Dr Malcolm Baxter, ENT Surgeon.

It is a focus on translational research in partnership with Monash University, the Monash Institute of Medical Research (MIMR) and Prince Henry's Institute of Medical Research (PHI). Together, the organisations form the Monash Health Translational Precinct.

The trial involved injecting directly into the vocal cords of patients with severe asthma that results in upper airway problems, Professor Bardin said.

"We trialed other methods of delivery, but we found the greatest benefit was achieved when we used a bronchoscope to guide our injections to a very specific area of tissue, where we inject a small amount of Botox," Professor Bardin said.

"This partially paralysed the muscles and caused the voice box to relax and allow air through."

A small cohort of 11 patients was chosen due to their severely impacting their daily lives and causing vocal cord dysfunction. They received a total of 24 injections, with approximately 60 per cent of those patients observing a significant reduction in symptoms.

"This treatment may not be suitable for all patients, but the early indicators are that it may be an option for those with severe upper airway distress, which is very exciting," Professor Bardin said.

"Many of these ' symptoms are extremely severe, so it has been tremendously satisfying to provide them with some relief."

Although Professor Bardin reinforced that more research is required, he also said objective measures such as CT scanners were able to show significant improvements in airway function.

"We are always conscious that injections can produce a strong placebo effect, but the CT results suggest the treatment has solid efficacy," Professor Bardin said.

add to favorites email to friend print save as pdf

Related Stories

Botox to iron out Australian asthma wrinkles

Jun 28, 2011

It is more celebrity than respiratory, but botox could prove a breath of fresh air for asthmatics if an Australian trial of the toxin launched Tuesday is successful.

Australians trial Botox to treat hay fever

Oct 09, 2012

The best-selling wrinkle erasing drug Botox will be used in an Australian study to treat hay fever, researchers said Tuesday after it showed promise in providing relief in early trials.

Vocal cord dysfunction may be caused by work

Sep 06, 2007

Researchers from the UAB and the Vall d'Hebron Hospital have diagnosed two patients affected with vocal cord dysfunction, which causes coughing and difficulty in breathing due to irritating agents that are breathed in at ...

Recommended for you

A better biomonitor for children with asthma

Dec 10, 2014

For the firefighters and rescue workers conducting the rescue and cleanup operations at Ground Zero from September 2001 to May 2002, exposure to hazardous airborne particles led to a disturbing "WTC cough"—obstructed ...

New insight into risk of Ankylosing Spondylitis

Dec 09, 2014

Scientists at the University of Southampton have discovered variations in an enzyme belonging to the immune system that leaves individuals susceptible to Ankylosing Spondylitis.

Novel approach to treating asthma: Neutralize the trigger

Dec 03, 2014

Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don't get to the root cause of the condition. Now, for the first time, scientists ...

Inflammatory discovery sheds new light on skin disease

Dec 02, 2014

Inflammatory skin diseases such as psoriasis may result from abnormal activation of cell death pathways previously believed to suppress inflammation, a surprise finding that could help to develop new ways ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.